Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.

Before installation, it’s crucial to understand that Microsoft Graph is a RESTful web API that integrates various Microsoft services. You only need to authenticate once to access data across these ...

The cybersecurity industry loves a good quote. At every conference, buried among the slide decks littered with questionable quotes from Sun Tzu's Art of War, you will occasionally strike gold and see ...

I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

Abstract: Graph representation learning is a fundamental research theme and can be generalized to benefit multiple downstream tasks from the node and link levels to the higher graph level. In practice ...

Rajiv Shesh is the Chief Revenue Officer at HCLSoftware where he leads revenue growth & customer advocacy for Products & Platforms division. What’s really powering AI? High-quality data—foundational ...

ABSTRACT: To effectively evaluate a system that performs operations on UML class diagrams, it is essential to cover a large variety of different types of diagrams. The coverage of the diagram space ...

In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s secretive drug discovery arm, Isomorphic Labs, is getting ready to ...